The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial.
Bernardo Bonanni
No relevant relationships to disclose
Patrick Maisonneuve
No relevant relationships to disclose
Davide Serrano
No relevant relationships to disclose
Clara Varricchio
No relevant relationships to disclose
Nicole Rotmensz
No relevant relationships to disclose
Massimiliano Cazzaniga
No relevant relationships to disclose
Matteo Lazzeroni
No relevant relationships to disclose
Barbara Santillo
No relevant relationships to disclose
Raffaella Di Pace
No relevant relationships to disclose
Antuono Latronico
No relevant relationships to disclose
Carlo Belloni
No relevant relationships to disclose
Marco Rosselli Del Turco
No relevant relationships to disclose
Nereo Segnan
No relevant relationships to disclose
Pietro Masullo
No relevant relationships to disclose
Claudio Andreoli
No relevant relationships to disclose
Nadia Monti
No relevant relationships to disclose
Alessandro Vella
No relevant relationships to disclose
Giuseppe D'Aiuto
No relevant relationships to disclose
Umberto Veronesi
No relevant relationships to disclose
Andrea De Censi
No relevant relationships to disclose